4-氯-N-乙基-3-吡啶磺酰胺 | 59582-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氯-N-乙基-3-吡啶磺酰胺
• 英文名称: 4-Chlorpyridin-3-ethylsulfonamid
• 英文别名: 4-chloro-pyridine-3-sulfonic acid ethylamide；4-Chloro-N-ethyl-3-pyridinesulfonamide；4-chloro-N-ethylpyridine-3-sulfonamide
• CAS: 59582-90-0
• 化学式: C₇H₉ClN₂O₂S
• 分子量: 220.68
• InChiKey: QITNZORWYWVLKV-UHFFFAOYSA-N

物化性质

• 熔点：
  139-140 °C(Solv: ligroine (8032-32-4))
• 沸点：
  351.7±52.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氯-N-乙基-3-吡啶磺酰胺 以80%的产率得到
  参考文献：
  名称：

  THUNUS L.; LAPIERE C.-L., ANN. PHARM. FRANC. , 1975 (1976), 33, NO 12, 663-669

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯吡啶- 3 -磺酰氯 、 乙胺 以80%的产率得到
  参考文献：
  名称：

  THUNUS L., ANN. PHARM. FRANC. , 1975, 33 NO 10, 487-494

  摘要：

  DOI：

文献信息

• Quinoxalinyl tripeptide hepatitis C virus inhibitors
  申请人：Gai Yonghua

  公开号：US20080032936A1

  公开（公告）日：2008-02-07

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药用可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投与含本发明化合物的药物组合物来治疗HCV感染的方法。
• THUNUS L.; LAPIERE C.-L., ANN. PHARM. FRANC. <APFR-AD>, 1975 (1976), 33, NO 12, 663-669
  作者：THUNUS L.、 LAPIERE C.-L.

  DOI：——

  日期：——
• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080317712A1

  公开（公告）日：2008-12-25

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• THUNUS L., ANN. PHARM. FRANC. <APFR-AD>, 1975, 33 NO 10, 487-494
  作者：THUNUS L.

  DOI：——

  日期：——